Enterotoxigenic Clostridium perfringens infection and pediatric patients with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 8, Issue 4, 2014, Pages 276-281

  Banaszkiewicz, Aleksandra ^a   Kądzielska, Joanna ^a   Gawrońska, Agnieszka ^a   Pituch, Hanna ^a   Obuch Woszczatyński, Piotr ^a   Albrecht, Piotr ^a   Młynarczyk, Grazyna ^a   Radzikowski, Andrzej ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Children; ; CPE; ; Crohn's disease; ; Enterotoxin; Ulcerative colitis;

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; ENTEROTOXIN; IMMUNOMODULATING AGENT; STEROID;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM PERFRINGENS INFECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENZYME IMMUNOASSAY; FECES ANALYSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; ULCERATIVE COLITIS; CASE CONTROL STUDY; CLOSTRIDIUM INFECTION; COLITIS, ULCERATIVE; COMPLICATION; DIARRHEA; FECES; FEMALE; INFLAMMATORY BOWEL DISEASES; MALE; MICROBIOLOGY;

CASE-CONTROL STUDIES; CHILD; CLOSTRIDIUM INFECTIONS; CLOSTRIDIUM PERFRINGENS; COLITIS, ULCERATIVE; CROHN DISEASE; DIARRHEA; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PROSPECTIVE STUDIES;

EID: 84895493361     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.08.018     Document Type: Article

References (44)

1. Bien J., Palagani V., Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?. Therap Adv Gastroenterol 2013, 6:53-68.
2. Rath H.C., Schultz M., Freitag R., Dieleman L.A., Li F., Linde H.J., et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001, 69:2277-2285.
3. Hansen R., Russell R.K., Reiff C., Louis P., McIntosh F., Berry S.H., et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol 2012, 107:1913-1922.
4. Docktor M.J., Paster B.J., Abramowicz S., Ingram J., Wang Y.E., Correll M., et al. Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:935-942.
5. Darfeuille-Michaud A., Boudeau J., Bulois P., Neut C., Glasser A.L., Barnich N., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2007, 127:412-421.
6. Sartor R.B., Mazmanian S.K. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol 2012, (Suppl. 1):15-21.
7. Howerton A., Patra M., Abel-Santos E. A new strategy for the prevention of Clostridium difficile infections. J Infect Dis 2013, 207:1498-1504.
8. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1432-1442.
9. Musa S., Thomson S., Cowan M., Rahman T. Clostridium difficile and inflammatory bowel disease. Scand J Gastroenterol 2010, 45:261-272.
10. Issa M., Vijayapal A., Graham M.B., Beaulieu D.B., Otterson M.F., Lundeen S., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:345-351.
11. Rodemann J.F., Dubberke E.R., Reske K.A., Seo da H., Stone C.D. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:339-344.
12. Pascarella F., Martinelli M., Miele E., Del Pezzo M., Roscetto E., Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009, 154:854-858.
13. Wultańska D., Banaszkiewicz A., Radzikowski A., Obuch-Woszczatyński P., Młynarczyk G., Brazier J.S., et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis 2010, 29:1265-1270.
14. Varga J., Stirewalt V.L., Melville S.B. The CcpA protein is necessary for efficient sporulation and enterotoxin gene (cpe) regulation in Clostridium perfringens. J Bacteriol 2004, 186:5221-5229.
15. Daube G., China B., Simon P., Hvala K., Mainil J. Typing of Clostridium perfringens by in vitro amplification of toxin genes. J Appl Bacteriol 1994, 77:650-655.
16. Skjelkvale R., Uemura T. Experimental diarrhoea in human volunteers following oral administration of Clostridium perfringens enterotoxin. J Appl Bacteriol 1977, 43:281-286.
17. Borriello S.P., Larson H.E., Welch A.R., Barclay F., Stringer M.F., Bartholomew B.A. Enterotoxigenic Clostridium perfringens: a possible cause of antibiotic-associated diarrhoea. Lancet 1984, 1:305-307.
18. Mpamugo O., Donovan T., Brett M.M. Enterotoxigenic Clostridium perfringens as a cause of sporadic cases of diarrhoea. J Med Microbiol 1995, 43:442-445.
19. Kobayashi S., Wada A., Shibasaki S., Annaka M., Higuchi H., Adachi K., et al. Spread of a large plasmid carrying the cpe gene and the tcp locus amongst Clostridium perfringens isolates from nosocomial outbreaks and sporadic cases of gastroenteritis in a geriatric hospital. Epidemiol Infect 2008, 137:108-113.
20. Hancock P. Antibiotic-associated diarrhea: Clostridium difficile or Clostridium perfringens?. Rev Med Microbiol 1997, 8(Suppl. 1):66-67.
21. Brett M.M., Rodhouse J.C., Donovan T.J., Tebbutt G.M., Hutchinson D.N. Detection of Clostridium perfringens and its enterotoxin in cases of sporadic diarrhoea. J Clin Pathol 1992, 45:609-611.
22. Carman R.J., Sayeed S., Li J., Genheimer C.W., Hiltonsmith M.F., Wilkins T.D., et al. Clostridium perfringens toxin genotypes in the feces of healthy North Americans. Anaerobe 2008, 14:102-108.
23. Vela M., Heredia N.L., Feng P., Santos García-Alvarado J. DNA probe analysis for the carriage of enterotoxigenic Clostridium perfringens in feces of a Mexican subpopulation. Diagn Microbiol Infect Dis 1999, 35:101-104.
24. Asha N.J., Tompkins D., Wilcox M.H. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 2006, 44:2785-2791.
25. Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
26. Mann E.A., Saeed S.A. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr Opin Gastroenterol 2012, 28:24-29.
27. Working I.B.D. Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005, 41:1-7.
28. Rousseeuw P.J., Croux C. Alternatives to the median absolute deviation. JASA 1993, 424:1273-1283.
29. Heimesaat M.M., Granzow K., Leidinger H., Liesenfeld O. Prevalence of Clostridium difficile toxins A and B and Clostridium perfringens enterotoxin A in stool samples of patients with antibiotic-associated diarrhea. Infection 2005, 33:340-344.
30. Pituch H., Obuch-Woszczatyński P., Wultańska D., van Belkum A., Meisel-Mikołajczyk F., Łuczak M. Laboratory diagnosis of antibiotic-associated diarrhea: a Polish pilot study into the clinical relevance of Clostridium difficile and Clostridium perfringens toxins. Diagn Microbiol Infect Dis 2007, 58:71-75.
31. Forward L.J., Tompkins D.S., Brett M.M. Detection of Clostridium difficile cytotoxin and Clostridium perfringens enterotoxin in cases of diarrhoea in the community. J Med Microbiol 2003, 52:753-757.
32. Goodhand J.R., Alazawi W., Rampton D.S. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:428-441.
33. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007, 104:13780-13785.
34. Sokol H., Seksik P., Rigottier-Gois L., Lay C., Lepage P., Podglajen I., et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:106-111.
35. Joossens M., Huys G., Cnockaert M., De Preter V., Verbeke K., Rutgeerts P., et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011, 60:631-637.
36. Smedley J.G., Saputo J., Parker J.C., Fernandez-Miyakawa M.E., Robertson S.L., McClane B.A., et al. Noncytotoxic Clostridium perfringens enterotoxin (CPE) variants localize CPE intestinal binding and demonstrate a relationship between CPE-induced cytotoxicity and enterotoxicity. Infect Immun 2008, 76:3793-3800.
37. Biagi E., Nylund L., Candela M., Ostan R., Bucci L., Pini E., et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010, 5:e10667.
38. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
39. Schneeweiss S., Korzenik J., Solomon D.H., Canning C., Lee J., Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009, 30:253-264.
40. Mezoff E., Mann E.A., Hart K.W., Lindsell C.J., Cohen M.B. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population. J Pediatr Gastroenterol Nutr 2011, 52:437-441.
41. Papa E., Docktor M., Smillie C., Weber S., Preheim S.P., Gevers D., et al. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One 2012, 7:e39242.
42. McClane B.A., Uzal F.A., Miyakawa M.F., Lyerly D., Wilkins T.D. The enterotoxic clostridia. The prokaryotes 2006, 688-752. Springer, New York, NY, USA. S. Falkow, M. Dworkin, E. Rosenburg, H. Schleifer, E. Stackebrandt (Eds.).
43. Collie R.E., Kokai-Kun J.F., McClane B.A. Phenotypic characterization of enterotoxigenic Clostridium perfringens isolates from non-foodborne human gastrointestinal diseases. Anaerobe 1998, 4:69-79.
44. Heikinheimo A., Lindström M., Granum P.E., Korkeala H. Humans as reservoir for enterotoxin gene-carrying Clostridium perfringens type A. Emerg Infect Dis 2006, 12:1724-1729.